Dr Alleyn Plowright is Chief Scientific Officer at Pangea Bio.
Alleyn is a seasoned drug discovery leader, with >20 years experience across a range of therapeutic areas, leading multi-disciplinary teams in AstraZeneca, Sanofi, and most recently as Head of Translational Science and Pre-clinical Development at Wren Therapeutics. He and his teams have contributed to the delivery of a range of compounds to the clinic, including two compounds currently in Phase 2 clinical trials.
Alleyn completed his PhD at the University of Nottingham, UK and postdoctoral studies at Harvard University. He has authored more than 70 publications and patents.